nach oben

Journal of Endocrinological Investigation

Erschienen in:

28.09.2023 | Original Article

The triglycerides and glucose index is more strongly associated with metabolically healthy obesity phenotype than the lipid and obesity indices

verfasst von: Y. Weyman-Vela, F. Guerrero-Romero, L. E. Simental-Mendía

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The triglycerides and glucose (TyG) index is a reliable biomarker for estimating insulin resistance; however, evidence regarding the use of the TyG index in individuals with metabolically healthy obesity (MHO) is scarce. Thus, we examined the association between the TyG index and the MHO phenotype.

Methods

Apparently healthy men and women aged 18 years or more with obesity (body mass index [BMI] ≥ 30 kg/m²) were allocated into the following groups: MHO and metabolically unhealthy obesity (MUO). The MHO phenotype was defined by obesity and the absence of the following metabolic disorders: elevated triglyceride concentrations, elevated glucose levels, elevated blood pressure, and low HDL-C. The MUO was defined by individuals with obesity and at least one of the aforementioned cardiovascular risk factors.

Results

A total 827 individuals, 605 (73.1%) women and 222 (26.9%) men were enrolled and allocated into the MHO (n = 104) and MUO (n = 723) groups. The adjusted regression analysis by age, sex, BMI, and waist circumference showed that fasting glucose (OR = 0.90; 95% CI: 0.88–0.93), and triglycerides (OR = 0.97; 95% CI: 0.96–0.98), as well as the triglycerides/HDL-C (OR = 0.18; 95% CI: 0.13–0.26), lipid accumulation product (OR = 0.95; 95% CI: 0.93–0.96), visceral adipose index (OR = 0.38; 95% CI: 0.31–0.46), and TyG index (OR = 0.001; 95% CI: 0.000–0.004) are inversely associated with the MHO, while the HDL-C (OR = 1.10; 95% CI: 1.07–1.12) had a direct association.

Conclusions

Our results show that the TyG index is more strongly associated with the MHO phenotype than the lipid and obesity indices.

Kivimäki M, Strandberg T, Pentti J et al (2022) Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. lancet Diabetes Endocrinol 10:253–263. https://doi.org/10.1016/S2213-8587(22)00033-XCrossRefPubMedPubMedCentral

Neeland IJ, Poirier P, Després JP (2018) Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137:1391–1406. https://doi.org/10.1161/CIRCULATIONAHA.117.029617CrossRefPubMedPubMedCentral

Bentham J, Di Cesare M, Bilano V et al (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet (London, England) 390:2627–2642. https://doi.org/10.1016/S0140-6736(17)32129-3CrossRef

Swinburn BA, Kraak VI, Allender S et al (2019) The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report. Lancet (London, England) 393:791–846. https://doi.org/10.1016/S0140-6736(18)32822-8CrossRefPubMed

Tsatsoulis A, Paschou SA (2020) Metabolically Healthy Obesity: Criteria, Epidemiology, Controversies, and Consequences. Curr Obes Rep 9:109–120. https://doi.org/10.1007/S13679-020-00375-0CrossRefPubMed

Liu C, Wang C, Guan S et al (2019) The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria. Obes Facts 12:78–90. https://doi.org/10.1159/000495852CrossRefPubMedPubMedCentral

Lavie CJ, Laddu D, Arena R et al (2018) Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol 72:1506–1531. https://doi.org/10.1016/J.JACC.2018.08.1037CrossRefPubMed

Blüher M (2020) Metabolically Healthy Obesity. Endocr Rev 41:405–420. https://doi.org/10.1210/ENDREV/BNAA004CrossRef

Messier V, Karelis AD, Prud’Homme D et al (2010) Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity (Silver Spring) 18:911–917. https://doi.org/10.1038/OBY.2009.364CrossRefPubMed

10.

Gómez-Zorita S, Queralt M, Vicente MA et al (2021) Metabolically healthy obesity and metabolically obese normal weight: a review. J Physiol Biochem 77:175–189. https://doi.org/10.1007/S13105-020-00781-XCrossRefPubMed

11.

Barrea L, Muscogiuri G, Pugliese G et al (2021) Metabolically healthy obesity (MHO) vs. metabolically unhealthy obesity (MUO) phenotypes in PCOS: association with endocrine-metabolic profile, adherence to the mediterranean diet, and body composition. Nutrients. https://doi.org/10.3390/nu13113925CrossRefPubMedPubMedCentral

12.

Succurro E, Marini MA, Frontoni S et al (2008) Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring) 16:1881–1886. https://doi.org/10.1038/OBY.2008.308CrossRefPubMed

13.

Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F (2008) The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6:299–304. https://doi.org/10.1089/MET.2008.0034CrossRefPubMed

14.

Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M et al (2010) The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 95:3347–3351. https://doi.org/10.1210/JC.2010-0288CrossRefPubMed

15.

Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A et al (2016) The TyG index may predict the development of cardiovascular events. Eur J Clin Invest 46:189–197. https://doi.org/10.1111/ECI.12583CrossRefPubMed

16.

Lei L, Liang H, Qu Y et al (2022) Association between triglyceride-glucose index and worsening renal function in the elderly. Front Nutr. https://doi.org/10.3389/FNUT.2022.951564CrossRefPubMedPubMedCentral

17.

Beran A, Ayesh H, Mhanna M et al (2022) Triglyceride-glucose index for early prediction of nonalcoholic fatty liver disease: a meta-analysis of 121,975 individuals. J Clin Med. https://doi.org/10.3390/JCM11092666CrossRefPubMedPubMedCentral

18.

Zaigham S, Tanash H, Nilsson PM, Muhammad IF (2022) Triglyceride-glucose index is a risk marker of incident copd events in women. Int J Chron Obstruct Pulmon Dis 17:1393–1401. https://doi.org/10.2147/COPD.S360793CrossRefPubMedPubMedCentral

19.

Scicali R, Di Pino A, Urbano F et al (2021) Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience. Nutr Metab Cardiovasc Dis 31:869–879. https://doi.org/10.1016/J.NUMECD.2020.11.009CrossRefPubMed

20.

Wang A, Tian X, Zuo Y et al (2021) Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study. Cardiovasc Diabetol. https://doi.org/10.1186/S12933-021-01305-7CrossRefPubMedPubMedCentral

21.

Kouvari M, Boutari C, Chrysohoou C et al (2021) Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. Clin Nutr 40:3314–3324. https://doi.org/10.1016/J.CLNU.2020.10.058CrossRefPubMed

22.

Lee YC, Park BJ, Lee JH (2021) Sex differences in the relationship between high-risk drinking and the triglyceride-glucose (TyG) index: an analysis using 2013 and 2015 korean national health and nutrition examination survey data. Alcohol Alcohol 56:393–400. https://doi.org/10.1093/ALCALC/AGAA122CrossRefPubMed

23.

Moon S, Park JS, Ahn Y (2017) The cut-off values of triglycerides and glucose index for metabolic syndrome in american and korean adolescents. J Korean Med Sci 32:427–433. https://doi.org/10.3346/JKMS.2017.32.3.427CrossRefPubMed

24.

Lee SH, Kwon HS, Park YM et al (2014) Predicting the development of diabetes using the product of triglycerides and glucose: the Chungju Metabolic Disease Cohort (CMC) study. PLoS One. https://doi.org/10.1371/JOURNAL.PONE.0090430CrossRefPubMedPubMedCentral

25.

Park HM, Lee HS, Lee YJ, Lee JH (2021) The triglyceride-glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance. Diabetes Res Clin Pract. https://doi.org/10.1016/J.DIABRES.2021.109042CrossRefPubMedPubMedCentral

26.

Zheng Y, Yin G, Chen F et al (2022) Evaluation of triglyceride glucose index and homeostasis model of insulin resistance in patients with polycystic ovary syndrome. Int J Womens Health 14:1821–1829. https://doi.org/10.2147/IJWH.S387942CrossRefPubMedPubMedCentral

27.

Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644CrossRefPubMed

28.

Amato MC, Giordano C, Galia M et al (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922. https://doi.org/10.2337/DC09-1825CrossRefPubMedPubMedCentral

29.

Kahn HS (2005) The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. https://doi.org/10.1186/1471-2261-5-26CrossRefPubMedPubMedCentral

30.

Gamboa-Gómez CI, Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F (2019) The fat-to-lean mass ratio, a novel anthropometric index, is associated to glucose metabolic disorders. Eur J Intern Med 63:74–78. https://doi.org/10.1016/J.EJIM.2019.03.017CrossRefPubMed

31.

Chobanian AV, Bakris GL, Black HR et al (1979) (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertens (Dallas. Tex 42(6):1206–1252. https://doi.org/10.1161/01.HYP.0000107251.49515.C2CrossRef

32.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502CrossRefPubMed

33.

Lopes WA, de Oliveira GH, Locateli JC, Simões CF (2020) TyG in insulin resistance prediction. J Pediatr (Rio J) 96:132–133. https://doi.org/10.1016/J.JPED.2019.09.002CrossRefPubMed

34.

Huang R, Cheng Z, Jin X et al (2022) Usefulness of four surrogate indexes of insulin resistance in middle-aged population in Hefei, China. Ann Med 54:622–632. https://doi.org/10.1080/07853890.2022.2039956CrossRefPubMedPubMedCentral

35.

Liu X, Tan Z, Huang Y et al (2022) Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. https://doi.org/10.1186/S12933-022-01546-0CrossRefPubMedPubMedCentral

36.

Akbar MR, Pranata R, Wibowo A et al (2021) The association between triglyceride-glucose index and major adverse cardiovascular events in patients with acute coronary syndrome - dose-response meta-analysis. Nutr Metab Cardiovasc Dis 31:3024–3030. https://doi.org/10.1016/J.NUMECD.2021.08.026CrossRefPubMed

37.

Wang Y, Yang W, Jiang X (2021) Association between triglyceride-glucose index and hypertension: a meta-analysis. Front Cardiovasc Med. https://doi.org/10.3389/FCVM.2021.644035CrossRefPubMedPubMedCentral

38.

Van MH, Tien HA, Sinh CT et al (2021) Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension. J Clin Hypertens (Greenwich) 23:529–537. https://doi.org/10.1111/JCH.14155CrossRef

39.

Wei A, Liu J, Wang L et al (2022) Correlation of triglyceride-glucose index and dyslipidaemia with premature coronary heart diseases and multivessel disease: a cross-sectional study in Tianjin. BMJ Open, China. https://doi.org/10.1136/BMJOPEN-2022-065780CrossRef

40.

Che B, Zhong C, Zhang R et al (2023) Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. Cardiovasc Diabetol. https://doi.org/10.1186/S12933-023-01762-2CrossRefPubMedPubMedCentral

41.

Pranata R, Huang I, Irvan et al (2021) The association between triglyceride-glucose index and the incidence of type 2 diabetes mellitus-a systematic review and dose-response meta-analysis of cohort studies. Endocrine 74:254–262. https://doi.org/10.1007/S12020-021-02780-4CrossRefPubMed

42.

da Silva A, Caldas APS, Rocha DMUP, Bressan J (2020) Triglyceride-glucose index predicts independently type 2 diabetes mellitus risk: a systematic review and meta-analysis of cohort studies. Prim Care Diabetes 14:584–593. https://doi.org/10.1016/J.PCD.2020.09.001CrossRefPubMed

43.

Wang Z, Zhao L, He S (2021) Triglyceride-glucose index as predictor for future type 2 diabetes mellitus in a Chinese population in southwest China: a 15-year prospective study. Endocrine 72:124–131. https://doi.org/10.1007/S12020-020-02589-7CrossRefPubMed

44.

Nabipoorashrafi SA, Seyedi SA, Rabizadeh S et al (2022) The accuracy of triglyceride-glucose (TyG) index for the screening of metabolic syndrome in adults: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 32:2677–2688. https://doi.org/10.1016/J.NUMECD.2022.07.024CrossRefPubMed

45.

Hoddy KK, Axelrod CL, Mey JT et al (2022) Insulin resistance persists despite a metabolically healthy obesity phenotype. Obesity (Silver Spring) 30:39–44. https://doi.org/10.1002/OBY.23312CrossRefPubMed

46.

Manu P, Ionescu-Tirgoviste C, Tsang J et al (2012) Dysmetabolic signals in “metabolically healthy” obesity. Obes Res Clin Pract 6:e1–e90. https://doi.org/10.1016/j.orcp.2011.04.003CrossRefPubMed

47.

Sejooti SS, Naher S, Hoque MM et al (2019) Frequency of insulin resistance in nondiabetic adult Bangladeshi individuals of different obesity phenotypes. Diabetes Metab Syndr 13:62–67. https://doi.org/10.1016/J.DSX.2018.08.022CrossRefPubMed

48.

Gonçalves CG, Glade MJ, Meguid MM (2016) Metabolically healthy obese individuals: key protective factors. Nutrition 32:14–20. https://doi.org/10.1016/J.NUT.2015.07.010CrossRefPubMed

49.

Liao C, Gao W, Cao W et al (2021) Associations of metabolic/obesity phenotypes with insulin resistance and c-reactive protein: results from the CNTR study. Diabetes Metab Syndr Obes 14:1141–1151. https://doi.org/10.2147/DMSO.S298499CrossRefPubMedPubMedCentral

50.

Marini MA, Frontoni S, Succurro E et al (2014) Differences in insulin clearance between metabolically healthy and unhealthy obese subjects. Acta Diabetol 51:257–261. https://doi.org/10.1007/S00592-013-0511-9CrossRefPubMed

51.

Bell JA, Hamer M, Batty GD et al (2015) Incidence of metabolic risk factors among healthy obese adults: 20-Year follow-up. J Am Coll Cardiol 66:871–873. https://doi.org/10.1016/J.JACC.2015.06.014CrossRefPubMedPubMedCentral

52.

Wildman RP, Muntner P, Reynolds K et al (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168:1617–1624. https://doi.org/10.1001/ARCHINTE.168.15.1617CrossRefPubMed

53.

van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN et al (2014) The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. https://doi.org/10.1186/1472-6823-14-9CrossRefPubMedPubMedCentral

54.

Ortega FB, Lavie CJ, Blair SN (2016) Obesity and cardiovascular disease. Circ Res 118:1752–1770. https://doi.org/10.1161/CIRCRESAHA.115.306883CrossRefPubMed

Titel: The triglycerides and glucose index is more strongly associated with metabolically healthy obesity phenotype than the lipid and obesity indices
verfasst von: Y. Weyman-Vela
F. Guerrero-Romero
L. E. Simental-Mendía
Publikationsdatum: 28.09.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 4/2024
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02201-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials

Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention

Adiponectin rs1501299 and chemerin rs17173608 gene polymorphism in children with type 1 diabetes mellitus: relation with macroangiopathy and peripheral artery disease

Deteriorated bone microarchitecture caused by sympathetic overstimulation in pheochromocytoma and paraganglioma

Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets